Literature DB >> 34283047

Role of Splicing Regulatory Elements and In Silico Tools Usage in the Identification of Deep Intronic Splicing Variants in Hereditary Breast/Ovarian Cancer Genes.

Alejandro Moles-Fernández1, Joanna Domènech-Vivó1, Anna Tenés2, Judith Balmaña1,3, Orland Diez1,2, Sara Gutiérrez-Enríquez1.   

Abstract

The contribution of deep intronic splice-altering variants to hereditary breast and ovarian cancer (HBOC) is unknown. Current computational in silico tools to predict spliceogenic variants leading to pseudoexons have limited efficiency. We assessed the performance of the SpliceAI tool combined with ESRseq scores to identify spliceogenic deep intronic variants by affecting cryptic sites or splicing regulatory elements (SREs) using literature and experimental datasets. Our results with 233 published deep intronic variants showed that SpliceAI, with a 0.05 threshold, predicts spliceogenic deep intronic variants affecting cryptic splice sites, but is less effective in detecting those affecting SREs. Next, we characterized the SRE profiles using ESRseq, showing that pseudoexons are significantly enriched in SRE-enhancers compared to adjacent intronic regions. Although the combination of SpliceAI with ESRseq scores (considering ∆ESRseq and SRE landscape) showed higher sensitivity, the global performance did not improve because of the higher number of false positives. The combination of both tools was tested in a tumor RNA dataset with 207 intronic variants disrupting splicing, showing a sensitivity of 86%. Following the pipeline, five spliceogenic deep intronic variants were experimentally identified from 33 variants in HBOC genes. Overall, our results provide a framework to detect deep intronic variants disrupting splicing.

Entities:  

Keywords:  cryptic splice sites; hereditary breast ovarian cancer; in silico prediction tools; pseudoexons; spliceogenic deep intronic variants; splicing regulatory elements

Year:  2021        PMID: 34283047     DOI: 10.3390/cancers13133341

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  4 in total

1.  Phenotype from SAMD9 Mutation at 7p21.2 Appears Attenuated by Novel Compound Heterozygous Variants at RUNX2 and SALL1.

Authors:  E Scott Sills; Samuel H Wood
Journal:  Glob Med Genet       Date:  2022-06-13

2.  Identification of an elusive spliceogenic MYBPC3 variant in an otherwise genotype-negative hypertrophic cardiomyopathy pedigree.

Authors:  Mario Torrado; Emilia Maneiro; Arsonval Lamounier Junior; Miguel Fernández-Burriel; Sara Sánchez Giralt; Ana Martínez-Carapeto; Laura Cazón; Elisa Santiago; Juan Pablo Ochoa; William J McKenna; Luis Santomé; Lorenzo Monserrat
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

3.  Analysis of Pathogenic Pseudoexons Reveals Novel Mechanisms Driving Cryptic Splicing.

Authors:  Niall P Keegan; Steve D Wilton; Sue Fletcher
Journal:  Front Genet       Date:  2022-01-24       Impact factor: 4.772

4.  Minigene-based splicing analysis and ACMG/AMP-based tentative classification of 56 ATM variants.

Authors:  Elena Bueno-Martínez; Lara Sanoguera-Miralles; Alberto Valenzuela-Palomo; Ada Esteban-Sánchez; Víctor Lorca; Inés Llinares-Burguet; Jamie Allen; Alicia García-Álvarez; Pedro Pérez-Segura; Mercedes Durán; Douglas F Easton; Peter Devilee; Maaike Pg Vreeswijk; Miguel de la Hoya; Eladio A Velasco-Sampedro
Journal:  J Pathol       Date:  2022-07-15       Impact factor: 9.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.